- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07348484
Układowy System Diagnostyczny i Monitorujący Chorobę Nerek Przewlekłą Oparty na Biomarkerach Moczu oraz Rzeczywista Skuteczność Inhibitorów SGLT2
Diagnostyczny i Monitorujący System Przewlekłej Choroby Nerek Oparty na Biomarkerach Moczu i Leczenie Prewencyjne z Zastosowaniem Inhibitora SGLT2 Empagliflozyny
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.
No investigational product is assigned, and medical practice or prescription patterns are not altered.
Przegląd badań
Szczegółowy opis
This is a real-world, observational study with prospective follow-up and retrospective baseline data when available, conducted at the Nephrology Department of the University Hospital of Salamanca, Spain.
The project integrates translational and clinical components:
- validation of a urinary biomarker panel obtained through differential proteomics for early detection and monitoring of CKD progression, and
- evaluation of the effectiveness and safety of SGLT2i in routine clinical practice.
A total of 300 adults with CKD stages 2-4 will be included (150 initiating SGLT2i and 150 matched controls). Participants will be followed for 12 months (baseline, 6, and 12 months). Data will be extracted exclusively from electronic health records and laboratory systems.
The primary outcome is the annual decline rate of estimated glomerular filtration rate (eGFR, CKD-EPI 2021). Secondary outcomes include a composite renal endpoint (≥40% sustained eGFR decline, renal replacement therapy, transplantation, or renal death), cardiovascular hospitalization, all-cause mortality, adverse drug reactions (ADRs), and real-world patterns of SGLT2i use.
Exploratory analyses will assess associations between urinary biomarkers and clinical outcomes.
The study follows Spanish regulations for observational studies with medicinal products (Real Decreto 957/2020), with ethics approval and informed consent for biological samples.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Carlos Martínez Salgado, PhD
- Numer telefonu: +34616129633
- E-mail: carlosms@usal.es
Lokalizacje studiów
-
-
-
Salamanca, Hiszpania
- Rekrutacyjny
- Hospital Universitario de Salamanca
-
Kontakt:
- Carlos Martínez Salgado, PhD
- Numer telefonu: +34616129633
- E-mail: carlosms@usal.es
-
Kontakt:
- Pilar Fraile Gómez, MD, PhD
- Numer telefonu: +34923291100
- E-mail: pilarfg@usal.es
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Participants with chronic kidney disease (CKD) stages 2-4.
Opis
Inclusion Criteria:
- ≥18 years old
- Diagnosed with chronic kidney disease (KDIGO stages 2-4)
- Life expectancy ≥12 months
- Available clinical and laboratory data in the electronic medical record
Exclusion Criteria:
- Current or recent renal replacement therapy or kidney transplantation
- End-stage renal disease
- Participation in interventional trials that may affect outcomes
- Allergy or intolerance to SGLT2i (for exposed cohort)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Empagliflozin Treatment Group
Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety. |
Oral empagliflozin (10-25 mg daily) for 12 months |
|
Control group
Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up. These patients receive standard clinical care according to local and national guidelines. They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems. Reasons for non-initiation of SGLT2i are documented systematically and may include: Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio <200 mg/g, eGFR <20 mL/min/1.73 m² for empagliflozin or <25 for dapagliflozin), or Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity. Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over). |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in urinary biomarker panel expression (proteomic fingerprint)
Ramy czasowe: Baseline, 6 months, 12 months
|
Quantitative assessment of urinary biomarkers (including KIM-1, transferrin, IGFBP7, TIMP-2, among others) to evaluate disease progression and treatment response. Urinary biomarkers will be assessed using liquid chromatography-mass spectrometry (LC-MS/MS)-based differential proteomic analysis. Biomarker expression will be quantified as log2 fold change with false discovery rate (FDR) correction. Selected biomarkers will be validated using enzyme-linked immunosorbent assay (ELISA) or equivalent immunoassays. Biomarker concentrations will be normalized to urinary creatinine levels. |
Baseline, 6 months, 12 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in estimated glomerular filtration rate (eGFR)
Ramy czasowe: Baseline, 6 months, 12 months
|
Evaluation of renal function improvement or stabilization during SGLT2 inhibitor treatment. |
Baseline, 6 months, 12 months
|
|
Histopathological improvement of renal tissue (animal study)
Ramy czasowe: Monthly up to 9 months
|
Monthly analysis of renal fibrosis, inflammation, and extracellular matrix accumulation in preclinical models treated with empagliflozin. |
Monthly up to 9 months
|
|
Monitoring of adverse events of empagliflozin in CKD patients without diabetes
Ramy czasowe: From baseline to 12 months
|
Adverse events (AEs) will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE, latest version), including severity grading and assessment of causality related to treatment. Serious adverse events (SAEs) and discontinuations due to AEs will be specifically tracked by the investigator. |
From baseline to 12 months
|
|
Change in estimated glomerular filtration rate (eGFR)
Ramy czasowe: From baseline to 12 months
|
Change in renal function assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation during empagliflozin treatment using the Serum creatinine-based CKD-EPI equation. |
From baseline to 12 months
|
|
Change in serum creatinine
Ramy czasowe: From baselinte to 12 months
|
hange in serum creatinine levels to assess renal safety during treatment with empagliflozin by standard clinical laboratory assay (mg/dL). |
From baselinte to 12 months
|
|
Change in urinary albumin-to-creatinine ratio
Ramy czasowe: From baseline to 12 months
|
Change in urinary albumin-to-creatinine ratio as a marker of renal damage and safety during empagliflozin treatment by standard urine laboratory testing (mg/g creatinine). |
From baseline to 12 months
|
|
Change in serum electrolyte levels
Ramy czasowe: From baseline to 12 months
|
Change in serum sodium and potassium levels to evaluate electrolyte safety during empagliflozin treatment by standard clinical laboratory testing (mmol/L). |
From baseline to 12 months
|
|
Change in liver function tests
Ramy czasowe: From baseline to 12 months
|
Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to assess hepatic safety by standard clinical laboratory assays (U/L). |
From baseline to 12 months
|
|
Change in glycated hemoglobin (HbA1c)
Ramy czasowe: From baseline to 12 months.
|
Change in HbA1c levels to monitor metabolic safety in non-diabetic CKD patients treated with empagliflozin by standard laboratory assay (%). |
From baseline to 12 months.
|
|
Change in hematological parameters
Ramy czasowe: From baseline to 12 months
|
Change in complete blood count parameters to evaluate hematological safety during treatment by standard clinical laboratory testing. |
From baseline to 12 months
|
|
Change in blood pressure
Ramy czasowe: From baseline to 12 months
|
Assessment of changes in both blood pressures (systolic and diastolic), by Standard sphygmomanometer measurement (mmHg). |
From baseline to 12 months
|
|
Change in body weight
Ramy czasowe: From baseline to 12 months
|
Change in body weight to assess tolerability and volume status during empagliflozin treatment by calibrated clinical scale (kg). |
From baseline to 12 months
|
|
Discontinuation due to treatment intolerance
Ramy czasowe: From baseline to 12 months
|
Number and proportion of participants who permanently discontinue empagliflozin due to treatment-related intolerance or adverse events. It will be achieved trough clinical visit records and adverse event reporting. |
From baseline to 12 months
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Carlos Martínez Salgado, PhD, University of Salamanca
- Główny śledczy: Pilar Fraile Gómez, MD, PhD, University of Salamanca
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Procesy patologiczne
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby nerek
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Przewlekła choroba
- Atrybuty choroby
- Niewydolność nerek
- Stany patologiczne, oznaki i objawy
- Niewydolność nerek, przewlekła
- empagliflozyna
Inne numery identyfikacyjne badania
- PI25/00053
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
Ramy czasowe udostępniania IPD
Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.
Kryteria dostępu do udostępniania IPD
Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ANALITYCZNY_KOD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .